Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03465748 · ClinicalTrials.gov registry record · NA
Effectiveness of Orthokeratology in Myopia Control
A NA study, sponsored by Illinois College of Optometry.
- Completed
- Registry status
- NA
- Development phase
- 45
- Enrollment target
NCT03465748: Completed NA study, sponsored by Illinois College of Optometry.
NCT03465748 is a NA study that has completed, run by Illinois College of Optometry. The registered enrollment target is 45 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03465748, a NA study, has completed, sponsored by Illinois College of Optometry.
- COMPLETED
- Registry status
- NA
- Development phase
- 45 participants
- Enrollment target
Study Summary
The high prevalence of myopia - especially in Asian countries - is well documented, as are the sight-threatening complications of high or degenerative myopia. Retinal detachment, glaucoma, vitreal degeneration and focal retinal changes may occur secondary to the progressive axial elongation of the eye with age. Specialty rigid lenses have long been shown to lessen this progression in the pediatric population; orthokeratology (ortho-k) lenses are worn at night and change the corneal topography to correct low to moderate amounts of myopia. Most of the studies on orthokeratology were conducted on Asian children. To the best of the investigators knowledge, no study has been done on African American (AA) children. The investigators' project seeks to investigate the efficacy of ortho-k in slowing axial elongation and myopic progression in AA children compared to that in other races.
Primary Outcome
Axial Length was measured at baseline and again at the 2 year mark. Units are given in mm. The average of axial length at the 2 year period is provided.
Interventions
- DEVICE OrthoK
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2017-05-01 |
| Est. Completion | 2021-12-01 |
| Phase | NA |
What the finished NCT03465748 record still lists
NCT03465748 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 45 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower).
The record links to 0 conditions, and to 1 intervention - of which OrthoK is the first listed.
NCT03465748 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03465748 about?
NCT03465748 is a clinical study titled "Effectiveness of Orthokeratology in Myopia Control". The high prevalence of myopia - especially in Asian countries - is well documented, as are the sight-threatening complications of high or degenerative myopia. Retinal detachment, glaucoma, vitreal degeneration and focal retinal changes may occur secondary to the progressive axial elongation of the e...
What is the current status of trial NCT03465748?
This trial is currently completed. It is a NA study. The enrollment target is 45 participants. The study started on 2017-05-01. Estimated completion is 2021-12-01.
What interventions are being tested in trial NCT03465748?
The interventions under investigation include: OrthoK (DEVICE).
Who is sponsoring clinical trial NCT03465748?
This trial is sponsored by Illinois College of Optometry, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03465748's enrollment target sits among peer trials
45 1411th of 2000 higher than 578 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00804154 · 45 participants · Phase 1
Resiniferatoxin to Treat Severe Pain Associated With Advanced Cancer
- NCT01851694 · 45 participants · NA
Beta-cell Response to Incretin Hormones in Cystic Fibrosis
- NCT02896335 · 45 participants · Phase 2
Palbociclib and Pembrolizumab In Central Nervous System Metastases
- NCT03454035 · 45 participants · Phase 1
Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI